Vu Tran, MD
Internal Medicine · Ruskin, FLNPI 1912961889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Astellas Pharma US Inc at 26.2% of the total. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 5 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$23
- Novo Nordisk$19
- AstraZeneca$15
- Pfizer$15
- GSK$15
Across 102 payments — averaging $16,844 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$1.7M
What the payments were for
- Food & beverage$87100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $23 |
| Novo Nordisk | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Pfizer | 1 | $15 |
| GSK | 1 | $15 |
How this compares
$87 in reported general payments places this provider in the 25th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $151,831 |
| ProliaDenosumab | 40 | $68,477 |
| JardianceEmpagliflozin | 48 | $68,351 |
| OzempicSemaglutide | 56 | $66,866 |
| XareltoRivaroxaban | 31 | $27,602 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $21,176 |
| MyrbetriqMirabegron | 37 | $20,476 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $14,804 |
| LinzessLinaclotide | 13 | $7,759 |
| Azelastine Hcl | 287 | $5,963 |
| Fluticasone Propionate | 481 | $5,603 |
| Levothyroxine Sodium | 524 | $5,106 |
| LumiganBimatoprost | 12 | $4,562 |
| Celecoxib | 285 | $4,042 |
| Diclofenac Sodium | 145 | $4,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $151,831188 claims |
| Novo NordiskOzempic | $19 | $66,86656 claims |
| GSKBreo Ellipta | $15 | $21,17641 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $20,47637 claims |
| AstraZenecaSymbicort | $15 | $14,80458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Ruskin
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.